Purpose: To evaluate the clinical outcomes of patients who underwent arthroscopic rotator cuff repair augmented using subacromial bursa, concentrated bone marrow aspirate (cBMA), and platelet-rich plasma.
Methods: Sixteen patients were included in the study who underwent arthroscopic rotator cuff repair augmented using subacromial bursa, cBMA, and platelet-rich plasma from January 2018 to July 2018 and had a minimum 1-year follow-up. American Shoulder and Elbow Surgeons (ASES), Simple Shoulder Test, Constant-Murley, and Single Assessment Numerical Evaluation (SANE) scores were collected preoperatively and at terminal follow-up. To determine the clinical relevance of ASES scores, the minimal clinically important difference, substantial clinical benefit, and the patient acceptable symptomatic state thresholds were used. In vitro cellular proliferation of subacromial bursa (nucleated cells/gram) and cBMA (nucleated cells and colony-forming units/cc) samples was evaluated and correlated to clinical outcomes scores.
Results: Mean follow-up was 12.6 ± 1.8 months (range 12-19 months). Patients achieved significant improvement in ASES (45.8±22.5 vs 88.5 ± 14.6 Δ44.7 ± 20.7; = .001), Simple Shoulder Test (4.3 ± 3.2 vs 10.4 ± 1.6, Δ5.7 ± 3.9, = .002), Constant-Murley (44.3 ± 18.2 vs 83.6 ± 17.5 Δ37.2 ± 21.8; = .001), SANE (13.3 ± 10.7 vs 86.3 ± 17.5 Δ71.9 ± 22.9; = .001), and pain scores (5.0±2.8 vs 1.1 ± 1.6 Δ3.5±2.5, = .001) at final follow-up. With regards to ASES score, 93.8% of patients achieved the minimal clinically important difference, 93.8% the substantial clinical benefit, and 62.5% reached or exceeded the patient acceptable symptomatic state criteria. There was a significant positive correlation of nucleated cell count of cBMA with postoperative SANE score (r = 0.707; = .015) and delta in ASES score (r = 0.727; = .011). All other correlations were found to be nonsignificant ( > .05, respectively).
Conclusions: Patients undergoing arthroscopic rotator cuff repair augmented using the Mega-Clot with bursa technique achieved significant improvement in functional outcomes at a minimum 1-year follow-up, with 93.8% of patients reaching substantial clinical benefit.
Level Of Evidence: Level IV, therapeutic case series.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754610 | PMC |
http://dx.doi.org/10.1016/j.asmr.2020.07.019 | DOI Listing |
Am J Sports Med
January 2025
Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Background: Interest in biological augmentation for improving bone-tendon interface (BTI) healing after arthroscopic rotator cuff repair (ARCR) is growing. Dermal fibroblasts, known for collagen synthesis similar to tenocytes, have shown effectiveness in BTI healing in chronic rotator cuff tear (RCT) models in rabbits. However, no human clinical trials have been conducted.
View Article and Find Full Text PDFActa Orthop Traumatol Turc
December 2024
Department of Orthopedics and Traumatology, Yıldırım Beyazıt University, Bilkent City Hospital, Ankara, Türkiye.
Objective: This study aimed to investigate the e!ect of arthroscopic Bankart repair (ABR) alone and ABR with an additional remplissage procedure on joint range of motion and functional results in patients with anterior shoulder instability.
Methods: This retrospective study included patients treated 1 year ago with either ABR alone or the ABR additional remplissage procedure. The Bankart lesion was determined by magnetic resonance imaging, and the amount of glenoid bone loss was determined by computed tomography.
Acta Orthop Traumatol Turc
December 2024
Department of Orthopedics, !e Second People's Hospital of Xiangcheng District, Suzhou, China.
Objective: The aim of this study was to examine if tranexamic acid (TXA) can assist in improving outcomes of arthroscopic rotator cu! repair (RCR).
Methods: The databases of PubMed, Embase, Web of Science, CENTRAL, and Scopus were searched for all types of studies examining the e"cacy of TXA for arthroscopic RCR. Twelve studies, 10 randomized controlled trials (RCTs), and 2 retrospective studies were considered eligible.
JSES Rev Rep Tech
February 2025
Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA.
Background: To perform an analysis of intraoperative costs associated with arthroscopic rotator cuff repair (RCR) acellular dermal allograft patch augmentation and interposition.
Methods: This was a matched cohort retrospective cost identification analysis. We identified patients who underwent arthroscopic RCR with acellular dermal allograft patch augmentation or interposition between 2014 and 2023 at a single academic center.
J Orthop
July 2025
Department of Orthopaedic Surgery, St. Luke's University Health Network, Bethlehem, PA, USA.
Background: Tranexamic acid (TXA) use has become the gold standard in total joint arthroplasty to limit intraoperative blood loss and transfusion rates. More recently, the indications for TXA have expanded to knee and shoulder arthroscopy with promising early results. However, the effectiveness of TXA during arthroscopic rotator cuff repair (RCR) is unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!